ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.5919
-0.06%
Brent Oil
83.655
0.07%
Bitcoin
66,923.18
1.15%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Travere Therapeutics Inc (TVTX)

  7. Travere Therapeutics Inc (TVTX) Noticias

TVTX

Travere Therapeutics (TVTX)

Travere Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:TVTX
FechaHoraFuenteTítuloSímboloCompañía
15/05/202416:00GlobeNewswire Inc.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TVTXTravere Therapeutics Inc
13/05/202415:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
10/05/202415:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
09/05/202415:30GlobeNewswire Inc.Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association CongressNASDAQ:TVTXTravere Therapeutics Inc
08/05/202415:30GlobeNewswire Inc.Travere Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:TVTXTravere Therapeutics Inc
06/05/202415:46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TVTXTravere Therapeutics Inc
06/05/202415:01GlobeNewswire Inc.Travere Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
29/04/202415:30GlobeNewswire Inc.Travere Therapeutics to Report First Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
24/04/202406:05GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
24/04/202402:00PR Newswire (Canada)CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
04/04/202415:30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians InternationalNASDAQ:TVTXTravere Therapeutics Inc
03/04/202415:30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses AssociationNASDAQ:TVTXTravere Therapeutics Inc
11/03/202406:05GlobeNewswire Inc.Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)NASDAQ:TVTXTravere Therapeutics Inc
23/02/202406:05GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
23/02/202401:00PR Newswire (US)CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathyNASDAQ:TVTXTravere Therapeutics Inc
20/02/202407:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TVTXTravere Therapeutics Inc
15/02/202415:01GlobeNewswire Inc.Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
14/02/202413:35Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TVTXTravere Therapeutics Inc
08/02/202415:30GlobeNewswire Inc.Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
01/02/202420:58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TVTXTravere Therapeutics Inc
01/02/202415:30GlobeNewswire Inc.Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:TVTXTravere Therapeutics Inc
25/01/202415:05GlobeNewswire Inc.Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian NationsNASDAQ:TVTXTravere Therapeutics Inc
08/01/202406:00GlobeNewswire Inc.Travere Therapeutics Provides Corporate Update and 2024 OutlookNASDAQ:TVTXTravere Therapeutics Inc
02/01/202415:30GlobeNewswire Inc.Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:TVTXTravere Therapeutics Inc
14/12/202306:30GlobeNewswire Inc.Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)NASDAQ:TVTXTravere Therapeutics Inc
04/12/202316:14Dow Jones NewsTravere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU TreatmentsNASDAQ:TVTXTravere Therapeutics Inc
04/12/202315:05GlobeNewswire Inc.Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGSNASDAQ:TVTXTravere Therapeutics Inc
21/11/202315:30GlobeNewswire Inc.Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:TVTXTravere Therapeutics Inc
07/11/202315:01GlobeNewswire Inc.Travere Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
03/11/202309:46GlobeNewswire Inc.Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023NASDAQ:TVTXTravere Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TVTX

Su Consulta Reciente

ZBCM
NEOUSDT
NEO
NASDAQ
SLNA
Selina Hospitality
COIN
QIEUR
BENQI
USOTC
ORXGF
Orca Energy (PK)
LSE
CAY
Charles Stanley
USOTC
SAENF
Solar Alliance Energy (PK)
COIN
YPLTUSD
yplutus.finance
COIN
RICKKUSD
Pick Or Rick
LSE
CHIB
Ct Uk High Income
BOV
V1OD34M
Vodafone
COIN
PKRUST
POLKER
LSE
USIG
Amundi Us Crp D
BIT
UV4LWP
UniCredit Bank
COIN
RUSDUST
Realio Network USD Stablecoin
NASDAQ
KERNW
Akerna
EU
ALTTI
Travel Technology Intera...
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados